Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ComPACT: ADG106 + Pembrolizumab in Advanced Solid Cancers and TNBC
NCT05491083Phase 2Recruiting
- Sponsor
- National University Hospital
- Start
- Jun 2023
- Primary completion
- Dec 2026
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ADG106 in solid tumor, triple-negative breast cancer (TNBC), sponsored by National University Hospital. Started Jun 2023; status: recruiting.
02
Drugs
ADG106
03
Conditions
solid tumortriple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05491083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05491083.